Chemomab director lists ADS stock option holdings
Chemomab Therapeutics Ltd. director Alan Charles Moses filed an initial Form 3 showing his holdings of stock options over American Depositary Shares.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
Chemomab Therapeutics Ltd. director Alan Charles Moses filed an initial Form 3 showing his holdings of stock options over American Depositary Shares. The filing lists several option grants at exercise prices ranging from $2.14 to $109.04 per ADS. According to the notes, these options are fully vested and exercisable as of the report date.
Insider Trade Summary
Holdings reported, no transactions
Holdings
Insider
Moses Alan Charles
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Stock option (right to buy American Depositary Shares) | -- | -- | -- |
| Holding | Stock option (right to buy American Depositary Shares) | -- | -- | -- |
| Holding | Stock option (right to buy American Depositary Shares) | -- | -- | -- |
| Holding | Stock option (right to buy American Depositary Shares) | -- | -- | -- |
| Holding | Stock option (right to buy American Depositary Shares) | -- | -- | -- |
| Holding | Stock option (right to buy American Depositary Shares) | -- | -- | -- |
Holdings:
Stock option (right to buy American Depositary Shares) — 17,903 contracts (Direct)
Footnotes (5)
- F1. The options reported in this row were granted to the Reporting Person by the Issuer on April 19, 2021, and are fully vested and exercisable as of the date of this report.
- F2. The options reported in this row were granted to the Reporting Person by the Issuer on March 7, 2022, and are fully vested and exercisable as of the date of this report.
- F3. The options reported in this row were granted to the Reporting Person by the Issuer on March 21, 2023, and are fully vested and exercisable as of the date of this report.
- F4. The options reported in this row were granted to the Reporting Person by the Issuer on March 18, 2024, and are fully vested and exercisable as of the date of this report.
- F5. The options reported in this row were granted to the Reporting Person by the Issuer on March 16, 2025, and are fully vested and exercisable as of the date of this report.
Key Figures
Option exercise price: $109.04 per ADS
Underlying ADS: 2,971 ADS
Option exercise price: $14.12 per ADS
+3 more
6 metrics
Option exercise price
$109.04 per ADS
Stock option expiring April 19, 2031
Underlying ADS
2,971 ADS
Option at $109.04 exercise price, direct holding
Option exercise price
$14.12 per ADS
Stock option expiring March 7, 2032
Underlying ADS
5,172 ADS
Option at $2.14 exercise price, expiring March 16, 2036
Lowest exercise price
$2.14 per ADS
Stock option expiring March 16, 2036
Intermediate exercise price
$6.16 per ADS
Stock option expiring March 16, 2035 covering 3,821 ADS
Key Terms
Form 3, Stock option, American Depositary Shares, fully vested and exercisable, +1 more
5 terms
Form 3 regulatory
"Chemomab Therapeutics Ltd. director Alan Charles Moses filed an initial Form 3"
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
Stock option financial
"Stock option (right to buy American Depositary Shares)"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
fully vested and exercisable financial
"are fully vested and exercisable as of the date of this report"
exercise price financial
"conversion_or_exercise_price: 2.1400"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Chemomab Therapeutics (CMMB) director Alan Charles Moses report on this Form 3?
He reports his existing holdings of stock options to buy Chemomab American Depositary Shares. The filing lists multiple option grants with specified exercise prices and expiration dates, providing a snapshot of his derivative-based equity position as a company director.
How many Chemomab ADS are covered by Alan Charles Moses’s reported stock options?
The filing lists several stock option grants, each tied to a specific number of underlying American Depositary Shares, such as 2,971, 1,705, 1,714, 2,520, 3,821, and 5,172 ADS, giving a detailed view of his option-based exposure to Chemomab’s equity.
What are the exercise prices of the Chemomab (CMMB) stock options held by Alan Charles Moses?
The reported stock options have exercise prices of $109.04, $14.12, $6.48, $2.96, $6.16 and $2.14 per American Depositary Share. These prices show the levels at which he can purchase Chemomab ADS if he chooses to exercise the options.
When do Alan Charles Moses’s Chemomab stock options expire?
The stock options expire on various future dates, including April 19, 2031, March 7, 2032, March 21, 2033, March 18, 2034, March 16, 2035 and March 16, 2036. These long-dated expirations outline the potential time window for exercising each grant.
Are the Chemomab stock options reported by Alan Charles Moses vested and exercisable?
According to the footnotes, the options reported for the respective grant dates are fully vested and exercisable as of the date of the report. This means he already satisfies the vesting conditions and can exercise those options within their stated expiration periods.
AI-generated analysis. How Rhea-AI works. Not financial advice.
